within Pharmacolibrary.Drugs.ATC.R;

model R03CB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 0.0085,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0028,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0034166666666666664,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R03CB03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Orciprenaline (also known as metaproterenol) is a selective beta-2 adrenergic agonist bronchodilator used for the treatment of asthma and other reversible obstructive airway diseases. It is now largely replaced by other more selective beta-2 agonists and is not commonly used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are from studies in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Jonkman, JH, &amp; Upton, RA (1984). Pharmacokinetic drug interactions with theophylline. <i>Clinical pharmacokinetics</i> 9(4) 309–334. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198409040-00002&quot;>10.2165/00003088-198409040-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6147220/&quot;>https://pubmed.ncbi.nlm.nih.gov/6147220</a></p></li><li><p>Hochhaus, G, &amp; Möllmann, H (1992). Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. <i>International journal of clinical pharmacology, therapy, and toxicology</i> 30(9) 342–362. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1358833/&quot;>https://pubmed.ncbi.nlm.nih.gov/1358833</a></p></li><li><p>Dengler, HG, &amp; Hengstmann, JH (1976). Metabolism and pharmacokinetics of orciprenaline in various animal species and man. <i>Archives internationales de pharmacodynamie et de therapie</i> 223(1) 71–87. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/999404/&quot;>https://pubmed.ncbi.nlm.nih.gov/999404</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R03CB03;
